The science of skin aging is evolving rapidly — and for women navigating the skin changes that come with menopause and beyond, evidence-based skincare represents a fundamentally different approach: working with your skin's biology rather than against it.
Unlike harsh exfoliants or retinoids that disrupt the skin barrier to force renewal, targeted active ingredients are messenger molecules that signal your own cells to produce more collagen, elastin, and protective proteins. The approach is gentle, evidence-based, and particularly suited to the thinner, more reactive skin that characterizes the post-menopausal years.
Evidence for Bakuchiol's Collagen-Boosting Effects
The collagen-stimulating properties of bakuchiol have been documented through a progression of evidence from molecular studies, in vitro cell culture experiments, and clinical trials in human subjects. The foundational in vitro work, published in the International Journal of Cosmetic Science in 2014, demonstrated that bakuchiol treatment of human dermal fibroblasts upregulated the expression of types I, III, and IV collagen genes by 72-96%, depending on collagen subtype and bakuchiol concentration. This magnitude of collagen gene upregulation is comparable to that achieved by all-trans-retinoic acid at equivalent concentrations (0.01-0.1%), establishing the molecular basis for bakuchiol's clinical anti-aging effects. Crucially, the study confirmed that bakuchiol's collagen stimulation was not mediated through retinoic acid receptors — when RAR antagonists were added to the cell culture, bakuchiol's collagen-stimulating effect was preserved while retinoic acid's was abolished — definitively proving an alternative signaling mechanism.[1]
The collagen synthesis pathway activated by bakuchiol centers on transforming growth factor-beta (TGF-β) signaling, one of the most potent endogenous drivers of fibroblast collagen production. Bakuchiol upregulates TGF-β1 expression in dermal fibroblasts, which binds TGF-β receptors on the cell surface, activating Smad2/3 phosphorylation and nuclear translocation — the canonical pathway that directly transactivates collagen gene promoters. A 2018 study in Molecular and Cellular Biochemistry mapped this pathway using selective inhibitors and confirmed that bakuchiol's collagen stimulation was abolished when TGF-β receptor kinase was blocked (SB431542 treatment), but was unaffected by retinoid receptor antagonists — cementing TGF-β as the primary mediator. Additionally, bakuchiol suppresses MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1) expression, protecting newly synthesized and existing collagen from enzymatic degradation. This dual mechanism — stimulating new collagen production while inhibiting existing collagen breakdown — produces a net positive collagen balance that is measurable histologically within 12 weeks of topical application.
Clinical research confirms that clinical evidence for bakuchiol's collagen effects in human skin comes primarily from the Dhaliwal et al. (2019) trial and subsequent supporting studies. In the Dhaliwal trial, the bakuchiol group demonstrated statistically significant improvements in wrinkle depth and skin elasticity — both clinical proxies for dermal collagen content — that were indistinguishable from the retinol group at 12 weeks. A 2020 follow-up study using high-resolution ultrasound to measure dermal thickness in women using 0.5% bakuchiol for 24 weeks documented a 9% increase in dermis thickness (from 1.32mm to 1.44mm mean), consistent with new collagen deposition. While this study lacked a retinol comparison arm, the magnitude of dermal thickening is within the range reported in retinoid studies of similar duration. Skin biopsy data specifically from bakuchiol-treated skin remains limited — most studies rely on non-invasive measures of collagen (ultrasound, elasticity measurements, wrinkle depth) rather than histological confirmation — representing a gap in the evidence base that future research will need to address.
The practical implications of bakuchiol's collagen-stimulating evidence for women over 40 are significant. During perimenopause and menopause, when collagen loss accelerates to approximately 2% per year, any intervention that stimulates new collagen synthesis has meaningful anti-aging value. Bakuchiol's collagen stimulation, combined with its MMP inhibition, creates a treatment that both replaces lost collagen and protects remaining collagen — addressing the two-pronged mechanism of menopausal collagen decline. For women who cannot use retinoids, bakuchiol provides the only clinically validated topical collagen-stimulating alternative with a retinol-equivalent evidence base. For women who can use retinoids, bakuchiol offers a complementary collagen stimulus through a non-redundant pathway (TGF-β versus RAR/RXR), suggesting potential for additive effects when used in combination or alternation with retinol — though controlled trials of this combination approach are still in early stages.
Your skin's capacity to repair and rebuild doesn't end at menopause — it just needs the right signals.
— Dr. Rachel Holbrook, Board-Certified Dermatologist
What This Means For Your Skin
If you've tried retinol and experienced irritation, or if your skin has become more sensitive with age, there is a path forward. The clinical evidence shows consistent, measurable improvement in wrinkle depth, skin firmness, and elasticity — without the adaptation period, peeling, or photosensitivity that other anti-aging actives demand.
Your skin's capacity to repair and rebuild doesn't diminish — it just needs the right support. A well-formulated skincare routine applied consistently for 8-12 weeks allows sufficient time for new collagen fibers to mature and integrate into your skin's existing matrix.
The science is clear. The evidence is consistent. The results are measurable.
What happens next is up to you.